Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015181749> ?p ?o ?g. }
- W2015181749 endingPage "18" @default.
- W2015181749 startingPage "9" @default.
- W2015181749 abstract "Aiming to address new drug targets, molecular modelling is gaining increasing importance although the prediction capability of the in silico method is still under debate. For an improved treatment of actinic keratosis and squamous cell carcinoma, inhibitors of human DNA polymerase alpha (pol alpha) are developed by docking nucleoside phosphonate diphosphates into the active site of pol alpha. The most promising prodrugs OxBu and OxHex were then prepared by total synthesis and tested in the squamous cancer cell line SCC25. OxBu and OxHex proved cytotoxic and antiproliferative in the nanomolar concentration range and thus exceeded activity of aphidicolin, the relevant model compound, and 5-fluorouracil, the current standard for the therapy of actinic keratosis. Interestingly, the cytotoxicity in normal human keratinocytes with OxHex was clearly less pronounced and even not detectable with OxBu. Moreover, cytotoxicity of OxBu in particular with the colorectal carcinoma cell line HT29 even surmounted cytotoxicity in SCC25, and other tumor cell lines were influenced, too, by both agents. Taken together, OxBu and OxHex may offer a new approach to cancer therapy, given the agents are sufficiently well tolerated in vivo which is to be suspected beside their chemical structure." @default.
- W2015181749 created "2016-06-24" @default.
- W2015181749 creator A5002454933 @default.
- W2015181749 creator A5007913429 @default.
- W2015181749 creator A5009383239 @default.
- W2015181749 creator A5010544570 @default.
- W2015181749 creator A5021234542 @default.
- W2015181749 creator A5053048742 @default.
- W2015181749 creator A5054344650 @default.
- W2015181749 creator A5071992983 @default.
- W2015181749 creator A5076551591 @default.
- W2015181749 creator A5081413658 @default.
- W2015181749 date "2010-09-01" @default.
- W2015181749 modified "2023-10-17" @default.
- W2015181749 title "Antitumor effects of guanosine-analog phosphonates identified by molecular modelling" @default.
- W2015181749 cites W1541037889 @default.
- W2015181749 cites W1586149291 @default.
- W2015181749 cites W1895525610 @default.
- W2015181749 cites W1911093385 @default.
- W2015181749 cites W1975392617 @default.
- W2015181749 cites W1983226581 @default.
- W2015181749 cites W1983727847 @default.
- W2015181749 cites W1983907637 @default.
- W2015181749 cites W1985110367 @default.
- W2015181749 cites W1991520044 @default.
- W2015181749 cites W2008453146 @default.
- W2015181749 cites W2009705590 @default.
- W2015181749 cites W2010053788 @default.
- W2015181749 cites W2012190601 @default.
- W2015181749 cites W2020302422 @default.
- W2015181749 cites W2021479709 @default.
- W2015181749 cites W2028319396 @default.
- W2015181749 cites W2028761028 @default.
- W2015181749 cites W2033406962 @default.
- W2015181749 cites W2034381586 @default.
- W2015181749 cites W2035816846 @default.
- W2015181749 cites W2040528315 @default.
- W2015181749 cites W2041986910 @default.
- W2015181749 cites W2042176139 @default.
- W2015181749 cites W2046017386 @default.
- W2015181749 cites W2047397273 @default.
- W2015181749 cites W2052693480 @default.
- W2015181749 cites W2059072956 @default.
- W2015181749 cites W2059245452 @default.
- W2015181749 cites W2064019766 @default.
- W2015181749 cites W2068950612 @default.
- W2015181749 cites W2072284949 @default.
- W2015181749 cites W2085465573 @default.
- W2015181749 cites W2086559292 @default.
- W2015181749 cites W2087674698 @default.
- W2015181749 cites W2089708325 @default.
- W2015181749 cites W2094388903 @default.
- W2015181749 cites W2107616878 @default.
- W2015181749 cites W2114055811 @default.
- W2015181749 cites W2125965253 @default.
- W2015181749 cites W2129913216 @default.
- W2015181749 cites W2137897859 @default.
- W2015181749 cites W2161811639 @default.
- W2015181749 cites W2167200314 @default.
- W2015181749 cites W2171526822 @default.
- W2015181749 cites W2950581729 @default.
- W2015181749 cites W2953242213 @default.
- W2015181749 cites W343719322 @default.
- W2015181749 cites W87555808 @default.
- W2015181749 doi "https://doi.org/10.1016/j.ijpharm.2010.06.036" @default.
- W2015181749 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20600723" @default.
- W2015181749 hasPublicationYear "2010" @default.
- W2015181749 type Work @default.
- W2015181749 sameAs 2015181749 @default.
- W2015181749 citedByCount "2" @default.
- W2015181749 countsByYear W20151817492014 @default.
- W2015181749 crossrefType "journal-article" @default.
- W2015181749 hasAuthorship W2015181749A5002454933 @default.
- W2015181749 hasAuthorship W2015181749A5007913429 @default.
- W2015181749 hasAuthorship W2015181749A5009383239 @default.
- W2015181749 hasAuthorship W2015181749A5010544570 @default.
- W2015181749 hasAuthorship W2015181749A5021234542 @default.
- W2015181749 hasAuthorship W2015181749A5053048742 @default.
- W2015181749 hasAuthorship W2015181749A5054344650 @default.
- W2015181749 hasAuthorship W2015181749A5071992983 @default.
- W2015181749 hasAuthorship W2015181749A5076551591 @default.
- W2015181749 hasAuthorship W2015181749A5081413658 @default.
- W2015181749 hasConcept C108215921 @default.
- W2015181749 hasConcept C109316439 @default.
- W2015181749 hasConcept C121608353 @default.
- W2015181749 hasConcept C142724271 @default.
- W2015181749 hasConcept C185592680 @default.
- W2015181749 hasConcept C202751555 @default.
- W2015181749 hasConcept C2756471 @default.
- W2015181749 hasConcept C2776253266 @default.
- W2015181749 hasConcept C2777546739 @default.
- W2015181749 hasConcept C2777873816 @default.
- W2015181749 hasConcept C2779998722 @default.
- W2015181749 hasConcept C2994460389 @default.
- W2015181749 hasConcept C2994491419 @default.
- W2015181749 hasConcept C3019992690 @default.
- W2015181749 hasConcept C502942594 @default.
- W2015181749 hasConcept C526805850 @default.